The Prognostic Value of IL-8 for the Death of Severe or Critical Patients with COVID-19
Overview
Authors
Affiliations
Inflammation has been believed to contribute to coronavirus disease 2019 (COVID-19). Risk factors for death of COVID-19 pneumonia have not yet been well established.In this retrospective cohort study, we included the deceased patients in COVID-19 specialized ICU with laboratory-confirmed COVID-19 from Guanggu hospital area of Tongji Hospital from February 8th to March 30th. Demographic, clinical, laboratory, and outcome data were extracted from electronic medical records using a standard data collection form. We used Spearman rank correlation and Cox regression analysis to explore the risk factors associated with in-hospital death, especially the association between inflammatory cytokines and death.A total of 205 severe/critical COVID-19 pneumonia patients were admitted in the COVID-19 specialized ICU and 75 deceased patients were included in the final analysis. The median age of the deceasing patients was 70 years (IQR 65-79). The common symptoms were fever (78.9%), cough (70.4%), and expectoration (39.4%). The BNP and CRP levels were far beyond the normal reference range. In the Spearman rank correlation analysis, IL-8 was found to be significantly associated with the time from onset to death (rs= -0.30, P = .034) and that from admission to death (rs= -0.32, P = .019). Cox regression showed after adjusting age and sex, IL-8 levels were still significantly associated with the time from onset to death (P = .003) and that from admission to death (P = .01).IL-8 levels were associated with in-hospital death in severe/critical COVID-19 patients, which could help clinicians to identify patients with high risk of death at an early stage.
Ling G, Su C, Guo Y, Qiu X, Liu J, Xiao M Front Pharmacol. 2024; 15:1472667.
PMID: 39559735 PMC: 11570807. DOI: 10.3389/fphar.2024.1472667.
Reconstructing the cytokine view for the multi-view prediction of COVID-19 mortality.
Wang Y, Wang Z, Liu Y, Yu Q, Liu Y, Luo C BMC Infect Dis. 2023; 23(1):622.
PMID: 37735372 PMC: 10514938. DOI: 10.1186/s12879-023-08291-z.
Li J, Guo S, Tan Y, Zhang J, Wu Z, Stalin A Medicine (Baltimore). 2023; 102(34):e34866.
PMID: 37653800 PMC: 10470725. DOI: 10.1097/MD.0000000000034866.
Iskandar A, Mayashinta D, Robert R, Samsu N, Endharti A, Widjajanto E Int J Gen Med. 2023; 16:2349-2354.
PMID: 37313045 PMC: 10259590. DOI: 10.2147/IJGM.S412070.
Lung fibrosis: Post-COVID-19 complications and evidences.
Hirawat R, Jain N, Saifi M, Rachamalla M, Godugu C Int Immunopharmacol. 2023; 116:109418.
PMID: 36736220 PMC: 9633631. DOI: 10.1016/j.intimp.2022.109418.